NATCO Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
May 29, 2023 at 02:22 pm IST
Share
NATCO Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 8,979 million compared to INR 5,968 million a year ago. Revenue was INR 9.27 million compared to INR 6,106 million a year ago. Net income was INR 2,758 million compared to net loss of INR 505 million a year ago. Basic earnings per share from continuing operations was INR 15.11 compared to basic loss per share from continuing operations of INR 2.77 a year ago. Diluted earnings per share from continuing operations was INR 15.11 compared to diluted loss per share from continuing operations of INR 2.77 a year ago.
For the full year, sales was INR 27,071 million compared to INR 19,448 million a year ago. Revenue was INR 28,117 million compared to INR 20,438 million a year ago. Net income was INR 7,153 million compared to INR 1,700 million a year ago. Basic earnings per share from continuing operations was INR 39.18 compared to INR 9.32 a year ago. Diluted earnings per share from continuing operations was INR 39.18 compared to INR 9.32 a year ago.
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Companyâs segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.